Home » Stocks » Zymeworks

Zymeworks Inc. (ZYME)

Stock Price: $41.32 USD 0.52 (1.27%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.89B
Revenue (ttm) 30.37M
Net Income (ttm) -172.82M
Shares Out 45.63M
EPS (ttm) -3.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $41.32
Previous Close $40.80
Change ($) 0.52
Change (%) 1.27%
Day's Open 40.82
Day's Range 40.52 - 41.94
Day's Volume 299,954
52-Week Range 20.33 - 52.75

More Stats

Market Cap 1.89B
Enterprise Value 1.46B
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 45.63M
Float 38.94M
EPS (basic) -3.91
EPS (diluted) -3.71
FCF / Share -2.79
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.98M
Short Ratio 3.26
Short % of Float 5.07%
Beta 0.75
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 62.09
PB Ratio 3.72
Revenue 30.37M
Operating Income -183.55M
Net Income -172.82M
Free Cash Flow -141.78M
Net Cash 428.30M
Net Cash / Share 9.39
Gross Margin -284.39%
Operating Margin -604.46%
Profit Margin -569.10%
FCF Margin -466.91%
ROA -22.47%
ROE -41.88%
ROIC -77.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (13)

Buy 11
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(28.82% upside)
Current: $41.32
Target: 53.23
*Average 12-month price target from 13 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-44.28%2.43%370.18%13.96%478.44%-
Gross Profit29.5453.0251.7611.019.661.67
Operating Income-151-33.36-9.47-37.86-19.96-12.75
Net Income-145-36.56-10.41-33.81-19.17-12.94
Shares Outstanding38.0229.0921.2512.7411.277.32
Earnings Per Share-3.83-1.26-0.64-2.65-1.70-1.77
Operating Cash Flow-81.8524.180.22-35.25-22.17-7.02
Capital Expenditures-6.32-0.80-2.02-4.43-0.63-0.08
Free Cash Flow-88.1823.37-1.80-39.67-22.80-7.10
Cash & Equivalents29920087.8040.2615.16-
Total Debt6.88--4.42--
Net Cash / Debt29220087.8035.8415.16-
Book Value2461801169.0018.24-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Zymeworks Inc.
Country Canada
Employees 295
CEO Ali Tehrani

Stock Information

Ticker Symbol ZYME
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSE: ZYME
IPO Date April 28, 2017


Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I and Phase II clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and other tumors; and ZW49, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced or metastatic HER2-expressing cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Company; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; collaboration with Applied BioMath, LLC.; and a research collaboration with ImmunoPrecise Antibodies Ltd. for the development of multiple antibody candidates to fight COVID-19. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.